drugset
drugset / Trial / NCT06693791

Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT

NCT06693791 ↗

Phase 2 Recruiting 34 enrolled Anhui Provincial Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of Romiplostim N01 for platelet recovery after umbilical cord blood transplantation (UCBT) in patients with hematological malignancies.

Timeline

Start
2024-12-01
Primary completion
2026-11-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Romiplostim Peptide 5 ug/kg Subcutaneous

Indications

transient neonatal thrombocytopenia